CeriBell (CBLL) Q2 Revenue Jumps 38%

CeriBell (NASDAQ:CBLL), the neurotechnology company specializing in rapid electroencephalography (EEG) and artificial intelligence for seizure detection, announced its results for Q2 2025 on August 5, 2025. The company’s revenue (GAAP) reached $21.2 million, up from $15.3 million in Q2 2024, outpacing the analyst consensus of $20.45 million (GAAP). Earnings per share (EPS, GAAP) were $(0.38), also better than the expected $(0.40) (GAAP). Despite significant top-line gains and a gross margin increase to 88% (GAAP), heavy investment in research, development, and commercial operations led to a wider net loss of $13.6 million (GAAP), compared to $8.9 million (GAAP) in Q2 2024. The quarter reflected strong commercial momentum, continued innovation, and a further commitment to market expansion. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. CeriBell focuses on improving detection and management of seizures in critical care settings via its portable Ceribell System, which combines a rapid EEG hardware platform with AI-powered algorithms. EEG, or electroencephalography, is a method of recording brain activity and is crucial for diagnosing seizures. Conventional hospital EEG systems are complex and slow to deploy, but CeriBell's portable solution enables real-time brain monitoring and interpretation at the patient’s bedside, even by non-specialists.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool